Search
2 results for “glp-1”
Topics
Health & Wellness
Ozempic vs. Mounjaro: New Heart Data From Europe's Biggest Diabetes Meeting Reignites the Rivalry
At EASD 2026 in Milan, Novo Nordisk presented real-world data from 636,525 adults linking escalated Ozempic 2 mg to 6% lower major cardiovascular event risk than switching to Mounjaro.
Meridian Newsroom30 Sept 20265 min read
Health & Wellness
Nearly 1 in 6 Teens on GLP-1 Drugs Developed a Nutritional Deficiency Within a Year
A Childhood Obesity study of 2,031 young patients found 16.9% were diagnosed with a nutritional deficiency within a year of starting GLP-1 treatment — yet only 5% received nutritional counseling within 30 days.
Meridian Newsroom30 Sept 20265 min read